Baidu
map

CD28/ICOS双重T细胞共刺激抑制剂ALPN-101用于预防和治疗急性移植物抗宿主病,同时斩获FDA的两个孤儿药称号

2020-03-20 MedSci原创 MedSci原创

Alpine Immune Sciences公司宣布,FDA已为其ALPN-101(选择性双重T细胞共刺激因子抑制剂)用于预防和治疗急性移植物抗宿主病(GVHD),指定了两个孤儿药称号。

Alpine Immune Sciences公司宣布,美国食品药品监督管理局(FDA)已为其ALPN-101(选择性双重T细胞共刺激因子抑制剂)用于预防和治疗急性移植物抗宿主病(GVHD),指定了两个孤儿药称号。

ALPN-101是诱导性T细胞共刺激配体(ICOSL)变体免疫球蛋白结构域(vIgDTM)的新型Fc融合蛋白,旨在同时抑制CD28和ICOS。CD28和ICOS是密切相关的共刺激分子,在T细胞活化中具有部分重叠功能,在多种自身免疫和炎性疾病中发挥重要作用。在移植物抗宿主病、炎性关节炎、结缔组织病和多发性硬化症的临床前模型中,ALPN-101的疗效优于单独阻断CD28-CD80/86和ICOS-ICOSL途径的药物。

移植物抗宿主病(GVHD)是造血细胞移植最常见的威胁生命的并发症。当供体细胞将受体细胞视为异源并攻击时,就会发生这种情况。急性GVHD通常发生在移植后的最初几周和几个月内,通常涉及皮肤、肝脏和胃肠道。

Alpine执行主席兼首席执行官Mitchell H. Gold博士说:"我们很高兴收到FDA在急性GVHD领域的孤儿药称号,因为目前的标准疗法仍不足以预防或控制该疾病。ALPN-101的独特机制有可能作为开创性药物,用于患有进行性和破坏性自身免疫/炎症患者,而如今他们很少或没有治疗选择。"

原始出处:

https://www.firstwordpharma.com/node/1708962?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-12-31 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-08-01 海豹
  5. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-08-04 jiekemin
  6. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-12-17 xuyong535
  7. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-03-22 wincls
  9. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1974487, encodeId=743a19e4487cb, content=<a href='/topic/show?id=2162235e38' target=_blank style='color:#2F92EE;'>#ALPN-101#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2357, encryptionId=2162235e38, topicName=ALPN-101)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jan 31 12:42:52 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852302, encodeId=6240185230241, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Dec 31 06:42:52 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685388, encodeId=68e21685388b9, content=<a href='/topic/show?id=22f84302f8' target=_blank style='color:#2F92EE;'>#CD28/ICOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4302, encryptionId=22f84302f8, topicName=CD28/ICOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06028165415, createdName=xiay994462, createdTime=Mon Apr 13 07:42:52 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791426, encodeId=23f71e91426ed, content=<a href='/topic/show?id=a608144254a' target=_blank style='color:#2F92EE;'>#PN-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14425, encryptionId=a608144254a, topicName=PN-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Aug 01 02:42:52 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036014, encodeId=d956203601479, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Tue Aug 04 12:42:52 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745341, encodeId=64061e4534175, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Thu Dec 17 15:42:52 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365227, encodeId=1728136522e40, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404744, encodeId=54221404e44db, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419733, encodeId=67e71419e33e3, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620751, encodeId=7f861620e5150, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Mar 22 08:42:52 CST 2020, time=2020-03-22, status=1, ipAttribution=)]

相关资讯

2020年克罗恩病和结肠炎大会:ALPN-101在体内和体外模型中均证明了治疗慢性炎症性肠病的功效

Alpine Immune Sciences是一家领先的疫疗法公司,致力于开发针对癌症和自身免疫炎性疾病的创新疗法,近日宣布,将在2020年克罗恩病和结肠炎大会上公布ALPN-101的临床前数据。

Baidu
map
Baidu
map
Baidu
map